Last reviewed · How we verify
NCT05766839
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
Phase 2 trial testing Patiromer in Hyperkalemia in 32 participants. Currently enrolling.
1 December 2029
Quick facts
| Lead sponsor | Vifor Pharma, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 6 April 2025 |
| Primary completion | 1 December 2029 |
| Estimated completion | 1 December 2030 |
| Sites | 37 locations across France, Italy, Finland, Greece, Belgium, Saudi Arabia, Israel, Poland |
Drugs / interventions tested
- Patiromer — full drug profile →
Conditions studied
- Hyperkalemia — all drugs for Hyperkalemia →
Sponsor
Vifor Pharma, Inc. — full company profile →
Who can join
Adults 0 to 11, any sex, with Hyperkalemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05766839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Patiromer
Trials testing the same drug.
- NCT04585542 — Comparison of Potassium Binders in the ER · Phase 4 · terminated
- NCT04142788 — RELieving Increasing oEdema Due to Heart Failure · Phase 4 · terminated
- NCT03888066 — Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure · Phase 3 · completed
- NCT03183778 — Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet. · Phase 4 · completed
- NCT03326583 — The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia · Phase 2 · completed
Other recruiting trials for Hyperkalemia
Currently open trials in the same condition.
- NCT06366230 — Adding Urea to the Final Dialysis Fluid · Phase 1, PHASE2 · recruiting
- NCT06884267 — Hyperkalemia Quality Improvement Program (HK-QIP) Study · NA · recruiting
- NCT06940414 — Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community · recruiting
- NCT06365684 — Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4 · Phase 4 · recruiting
- NCT06635590 — Chronic Kidney Disease, Hyperkalemia and Echocardiographic Changes · recruiting
Other Vifor Pharma, Inc. trials
Trials by the same sponsor.
- NCT03888066 — Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure · Phase 3 · completed
- NCT03087058 — Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia · Phase 2 · terminated
- NCT05861492 — FDDA Utilization Study (FDDAU) · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05766839 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vifor Pharma, Inc.
- Last refreshed: 13 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05766839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing